Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
NULIBRY (FOSDENOPTERIN HYDROBROMIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
NULIBRY
NDA
Get alerts
FOSDENOPTERIN HYDROBROMIDE | N214018 | SENTYNL THERAPEUTICS INC
1 strength
1 unique patent
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
1 unique patent, 2 exclusivities by expiration date
Active (1)
Today
Exclusivity
2026
2027
2028
2029
Today
7504095
Apr. 9, 2029
NCE
Feb. 26, 2026
ODE-342
Feb. 26, 2028
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 9.5MG BASE/VIAL
RLD
1 patent
2 exclusivities
▴
POWDER;INTRAVENOUS | Approved: Feb 26, 2021
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7504095
Apr 9, 2029
—
—
Yes
U-3092
METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A
—
Exclusivities (2)
Code
Date
Status
NCE
Feb 26, 2026
Expired
ODE-342
Feb 26, 2028
Active